Director/PDMR Shareholding
Updated : 15:06
Collagen Solutions Plc
(the "Company" or the "Group")
Director/PDMR Dealing
The Company today announces that on 25 September 2018 David Evans, Chairman of the Company, has purchased 650,000 ordinary shares in the Company ("Ordinary Shares") at 3.75 pence per Ordinary Share.
Following these purchases, David Evans' total beneficial holding in the Company has increased to 43,187,411 Ordinary Shares representing 13.31 per cent. of the issued ordinary share capital of the Company.
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | David Evans | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chairman | ||||
b) | Initial notification / Amendment | Initial | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | COLLAGEN SOLUTIONS PLC | ||||
b) | LEI | 213800IFY1CVGRGETL95 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 1p each | ||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information |
| ||||
e) | Date of the transaction | 25 September 2018 | ||||
f) | Place of the transaction | London Stock Exchange, XLON | ||||
Enquiries:
Collagen Solutions Plc |
| ||
Jamal Rushdy, CEO | Via Walbrook | ||
Hilary Spence, CFO |
| ||
|
| ||
Cenkos Securities Plc (Nominated Adviser and Broker) |
| ||
Steve Cox (Corporate Finance) | Tel: 0207 397 8900 | ||
Stephen Keys |
| ||
|
| ||
Walbrook PR Ltd | Tel: 020 7933 8780 or collagen@walbrookpr.com | ||
Anna Dunphy | Mob: 07876 741 001 | ||
Helen Cresswell | Mob: 07841 917 679 | ||
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.